We are currently experiencing periodic technical issues with our website forms. If you would like to schedule an appointment or require immediate assistance, please call 800-836-7536.

800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Temple University Hospital to Study Experimental Stroke Drug

View All News

Temple University Hospital (TUH) will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor VIIa (rFVIIa), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage (ICH).

The study entitled “Recombinant Factor VIla (rFVIla) for Acute Hemorrhagic Stroke Administered at Earliest Time,” also referred to as the FASTEST trial, is funded by the National Institutes of Health (NIH). The research will be conducted at Temple University Hospital. Participants in the clinical trial will receive either the experimental drug rFVlla or a placebo (no active ingredient), and the best standard medical care.

ICH accounts for more than 10% of the estimated 17 million strokes worldwide each year and is the deadliest type of stroke with a mortality rate of more than 40%. Currently, there is no effective treatment for ICH.

“We are pleased that Temple University Hospital will be one of the sites participating in the FASTEST clinical trial and researching the drug rFVlla given the lack of treatments available for this deadly condition,” said Nina Gentile, MD, Professor and Vice Chair for Research in the Department of Emergency Medicine at the Lewis Katz School of Medicine at Temple University and Principal Investigator for the trial at TUH.

The study will include adults from 18 through 80 years old with ICH. The study medicine will be given within two hours of stroke onset. Because acute ICH is a life-threatening condition requiring immediate treatment, some patients will be enrolled using delayed consent if unconscious and a family member or other representative is not readily available. Every attempt will be made to locate family prior to enrollment to allow them to decide about the patient’s participation in the study.

Before the study starts at Temple University Hospital, one of the requirements to be a participating site is to engage in community outreach efforts to provide information, answer questions and get community members’ input about this important clinical research. Temple University Hospital will be reaching out to community members to gain as much input as possible.

For more information about the research study, visit https://nihstrokenet.org/fastest/community-resources or https://redcap.link/FASTEST or contact Dr. Gentile and the study team at EDResearch@tuhs.temple.edu.